Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Emergent Biosolutions (EBS)
NYSE:EBS
Holding EBS?
Track your performance easily
Earnings Data
Report Date
Feb 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.41Last Year’s EPS
-$0.77Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2024
|% Change Since: -11.96%
|Next Earnings Date:Feb 20, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements such as the completion of the stabilization phase, improved financial performance, debt reduction, and increased product sales. However, some challenges remain, particularly in maintaining competitive pricing for NARCAN and managing revenue timing for medical countermeasures. Overall, the positive developments seem to outweigh the challenges.Company Guidance
During the Q3 2024 earnings call for Emergent BioSolutions, the company provided updated guidance and detailed several financial metrics. The company reported total revenues of $294 million for the quarter, marking a 9% year-over-year increase. Adjusted EBITDA was $105 million, representing 36% of revenues and an $85 million improvement from the previous year. The company also highlighted a strengthened balance sheet with net debt reduced by $206 million since the beginning of 2024. Emergent raised its full-year revenue guidance to between $1.065 billion and $1.125 billion, and adjusted EBITDA guidance to between $180 million and $200 million. The company emphasized its progress on operational improvements, including a $377 million year-over-year improvement in operating cash flow and a $98 million reduction in net working capital. Additionally, Emergent noted upgrades in its corporate family credit ratings by Moody's and S&P.Completion of Stabilization Phase
Emergent BioSolutions completed the stabilization phase ahead of expectations as part of their multiyear plan to transform and strengthen the business.
Financial Performance and Guidance Increase
Emergent finished the quarter in its strongest financial position since 2021. They raised the revised midpoint for 2024 revenue and adjusted EBITDA full-year guidance.
Debt Reduction and Refinancing
Net debt was reduced by more than $200 million in 2024. A new credit facility agreement was closed, refinancing debt and improving credit ratings.
Medical Countermeasure Contracts
Over $500 million in contract modifications for Anthrax, Smallpox MCM, and BAT were received, strengthening revenue diversification.
NARCAN Sales and Public Health Contributions
NARCAN Nasal Spray volumes increased year-to-date. FDA approval for ACAM2000 for treating mpox and significant contracts for medical countermeasures were secured.
Operational Cost Reductions
Operating expenses improved significantly, with a notable reduction in compensation and legal fees due to restructuring initiatives.
---
EBS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
EBS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $9.20 | $11.00 | +19.57% |
| Aug 06, 2024 | $9.86 | $5.72 | -41.99% |
| May 01, 2024 | $1.93 | $3.30 | +70.98% |
| Mar 06, 2024 | $3.26 | $2.77 | -15.03% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Emergent Biosolutions (EBS) report earnings?
Emergent Biosolutions (EBS) is schdueled to report earning on Feb 20, 2025, TBA Not Confirmed.
What is Emergent Biosolutions (EBS) earnings time?
Emergent Biosolutions (EBS) earnings time is at Feb 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EBS EPS forecast?
EBS EPS forecast for the fiscal quarter 2024 (Q4) is -$0.41.
---